The researcher is Steven Goodman, PhD, associate professor of pediatrics at the Ohio State College of Medicine, principal investigator at the Research Institute of Nationwide Children’s Hospital in Columbus and a member of the scientific board for Ohio-based biotechnology company ProclaRx.
According to Dr. Goodman, ProclaRx’s new technology can break down the physical barriers that protect bacteria and prevent antibiotics from attacking chronic infections.
ProclaRx CEO Joseph D. Kittle Jr., PhD, noted the technology is “unusual in that it can support both therapeutic as well as medical device products.”
More articles on bacterial infections:
Researchers reveal ‘tentacles’ UTI bacteria use to stay put during infection
Princeton researchers show how bacteria communicate, create infections
Deadly bacteria flew under many scientists’ radar, until now: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.